Prof. Timothy Andersson Email & Phone Number

Genetic biotechnologies are thriving at an unprecedented pace while instrumentally allowing religious and financial interest opportunists to halt the progress. To me advances in medicine dictate courage, vision, diligence, perseverance, determination and the uncompromising ability to do where others fear and reluctant to tread. Why not, think the unthinkable. Often said, success is 99% perspiration and 1% inspiration. Pluto recognized beauty as privilege of nature and Aristotle appreciated beauty as a gift from God. Among female and male facial beautification realm has extended beyond conventional therapies. Yet, there is no fool-proof remedy. On the other side among male stress is causing more and more erectile dysfunction (ED) with no definite cure. Most of the prescription medications in the market are meant to create dependency (use it or lose it), drug must move from the shelf. Medicine is now a business and not a mission anymore.The multipotency and proliferative capacity of hESCs and iPSCs have envisioned to be a major promising source for patient-specific transplant therapies. Derivation of patient-specific syngenic hESC lines offered the prospect of autologous stem cells that are likely to prevent allorecognition. To avoid ethical or legal limitations the best substitute is incorporation of plant stem cells. I have conducted phase three clinical studies and have observed that the treatments were remarkably responsive with encouraging results. The studies demonstrated that plant stem cells in a proprietary vehicle were safe, tolerable and significantly more beneficial in contributing superior clinical efficacy to treat psoriasis, acne, rosacea, melasma, reverse aging and ED.Besides many published articles and reviewer in many reputable medical journals and the most erudite invited speaker, I have more than forty years of professional expertise in this field and I am open to mutual collaboration with potential partner. Please feel free to contact.

Listed skills include Lifesciences, Cell Culture, Technology Transfer, Genomics, and 44 others.